On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

United States’ Food and Drug Administration landed on a major decision regarding the pain medication and the tendency for ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The FDA approves suzetrigine, a non-opioid pain medication, offering a safer alternative to opioids for pain management, ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...